Yanan Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1030670/publications.pdf Version: 2024-02-01



ΥΛΝΑΝ ΖΗΛΝΟ

#	Article	IF	CITATIONS
1	A Modular Synthesis of the Lamellarins:  Total Synthesis of Lamellarin G Trimethyl Ether. Journal of Organic Chemistry, 2004, 69, 2362-2366.	1.7	111
2	A simple guide for predicting regioselectivity in the coupling of polyhaloheteroaromatics. Chemical Communications, 2006, , 299-301.	2.2	106
3	APPROACHES TO THE SYNTHESIS OF THE LAMELLARINS AND RELATED NATURAL PRODUCTS. A REVIEW. Organic Preparations and Procedures International, 2005, 37, 411-445.	0.6	89
4	Layer-by-layer modification of magnetic graphene oxide by chitosan and sodium alginate with enhanced dispersibility for targeted drug delivery and photothermal therapy. Colloids and Surfaces B: Biointerfaces, 2019, 176, 462-470.	2.5	79
5	Effects of the Trace Amine-Associated Receptor 1 Agonist RO5263397 on Abuse-Related Effects of Cocaine in Rats. Neuropsychopharmacology, 2014, 39, 2309-2316.	2.8	78
6	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Medicinal Research Reviews, 2017, 37, 441-474.	5.0	76
7	Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Current Topics in Medicinal Chemistry, 2019, 19, 1418-1435.	1.0	69
8	An unusual dehalogenation in the Suzuki coupling of 4-bromopyrrole-2-carboxylates. Tetrahedron Letters, 2003, 44, 427-430.	0.7	62
9	Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor. Journal of Medicinal Chemistry, 2010, 53, 7048-7060.	2.9	62
10	Imidazoline I2 receptors: Target for new analgesics?. European Journal of Pharmacology, 2011, 658, 49-56.	1.7	60
11	Design and Synthesis of Cannabinoid Receptor 1 Antagonists for Peripheral Selectivity. Journal of Medicinal Chemistry, 2012, 55, 2820-2834.	2.9	57
12	Recent advances of boronate affinity materials in sample preparation. Analytica Chimica Acta, 2019, 1076, 1-17.	2.6	56
13	Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug and Alcohol Dependence, 2014, 143, 251-256.	1.6	55
14	Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine. Neuropsychopharmacology, 2018, 43, 1001-1009.	2.8	51
15	Serine metabolism antagonizes antiviral innate immunity by preventing ATP6V0d2-mediated YAP lysosomal degradation. Cell Metabolism, 2021, 33, 971-987.e6.	7.2	51
16	Excellent antitumor and antimetastatic activities based on novel coumarin/pyrazole oxime hybrids. European Journal of Medicinal Chemistry, 2019, 166, 470-479.	2.6	48
17	The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats. Neuroscience Letters, 2014, 566, 67-71.	1.0	46
18	Role of TAAR1 within the Subregions of the Mesocorticolimbic Dopaminergic System in Cocaine-Seeking Behavior. Journal of Neuroscience, 2017, 37, 882-892.	1.7	45

#	Article	IF	CITATIONS
19	Antihyperalgesic effects of imidazoline <scp>I</scp> ₂ receptor ligands in rat models of inflammatory and neuropathic pain. British Journal of Pharmacology, 2014, 171, 1580-1590.	2.7	43
20	Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Research, 2020, 1731, 145922.	1.1	43
21	Effects of the Trace Amine Associated Receptor 1 Agonist RO5263397 on Abuse-Related Behavioral Indices of Methamphetamine in Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu060-pyu060.	1.0	42
22	Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure–Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). Journal of Medicinal Chemistry, 2014, 57, 7758-7769.	2.9	40
23	Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects. Neuropsychopharmacology, 2018, 43, 2435-2444.	2.8	39
24	Protection of poorly nucleophilic pyrroles. Tetrahedron Letters, 2004, 45, 5057-5060.	0.7	37
25	Emerging drug targets for pain treatment. European Journal of Pharmacology, 2012, 681, 1-5.	1.7	37
26	Effects of imidazoline I2 receptor ligands on morphine- and tramadol-induced antinociception in rats. European Journal of Pharmacology, 2011, 670, 435-440.	1.7	36
27	Characterization of the hypothermic effects of imidazoline I ₂ receptor agonists in rats. British Journal of Pharmacology, 2012, 166, 1936-1945.	2.7	36
28	Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor. Journal of Medicinal Chemistry, 2013, 56, 6901-6916.	2.9	36
29	Behavioral effects of the cannabinoid CB ₁ receptor allosteric modulator ORG27569 in rats. Pharmacology Research and Perspectives, 2014, 2, e00069.	1.1	36
30	Boronate affinity Metal–Organic frameworks for highly efficient cis-diol molecules in-situ enrichment and surface-assisted laser desorption/ionization mass spectrometric detection. Analytica Chimica Acta, 2019, 1065, 40-48.	2.6	35
31	Morphine-induced antinociception in the rat: Supra-additive interactions with imidazoline I2 receptor ligands. European Journal of Pharmacology, 2011, 669, 59-65.	1.7	34
32	Advances in curcumin-loaded nanopreparations: improving bioavailability and overcoming inherent drawbacks. Journal of Drug Targeting, 2019, 27, 917-931.	2.1	34
33	Bicomponent polymeric micelles for pH-controlled delivery of doxorubicin. Drug Delivery, 2020, 27, 344-357.	2.5	34
34	Recent advances in electrospun for drug delivery purpose. Journal of Drug Targeting, 2019, 27, 270-282.	2.1	33
35	Diphenyl Purine Derivatives as Peripherally Selective Cannabinoid Receptor 1 Antagonists. Journal of Medicinal Chemistry, 2012, 55, 10022-10032.	2.9	31
36	Structure–activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorganic and Medicinal Chemistry, 2015, 23, 2195-2203.	1.4	31

Yanan Zhang

#	Article	IF	CITATIONS
37	Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the Â-Opioid Receptor. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 509-519.	1.3	30
38	Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor. Journal of Medicinal Chemistry, 2018, 61, 4370-4385.	2.9	30
39	Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5711-5714.	1.0	29
40	Effects of Trace Amine-associated Receptor 1 Agonists on the Expression, Reconsolidation, and Extinction of Cocaine Reward Memory. International Journal of Neuropsychopharmacology, 2016, 19, pyw009.	1.0	29
41	Recent progress of functionalised graphene oxide in cancer therapy. Journal of Drug Targeting, 2019, 27, 125-144.	2.1	28
42	Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4064-4067.	1.0	26
43	Methamphetamine-induced impulsivity during chronic methamphetamine treatment in rats: Effects of the TAAR 1 agonist RO5263397. Neuropharmacology, 2018, 129, 36-46.	2.0	26
44	Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats. Pharmacology Biochemistry and Behavior, 2012, 103, 332-337.	1.3	25
45	Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers. ACS Medicinal Chemistry Letters, 2014, 5, 634-638.	1.3	25
46	Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Rasâ€Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation. ChemMedChem, 2015, 10, 971-976.	1.6	24
47	Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. British Journal of Anaesthesia, 2020, 125, 596-604.	1.5	24
48	The great divide: Separation between inÂvitro and inÂvivo effects of PSNCBAM-based CB 1 receptor allosteric modulators. Neuropharmacology, 2017, 125, 365-375.	2.0	23
49	Effects of imidazoline I2 receptor ligands on acute nociception in rats. NeuroReport, 2012, 23, 73-77.	0.6	22
50	ldentification of 1-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1 <i>H</i> -pyrazol-3-yl]carbonyl}amino)cyclohexane Carboxylic Acid as a Selective Nonpeptide Neurotensin Receptor Type 2 Compound. Journal of Medicinal Chemistry, 2014, 57, 5318-5332.	2.9	21
51	Effects of the imidazoline I ₂ receptor agonist 2â€BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats. British Journal of Pharmacology, 2016, 173, 1363-1372.	2.7	21
52	Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. Journal of Medicinal Chemistry, 2017, 60, 7410-7424.	2.9	21
53	A silver-catalyzed radical ring-opening reaction of cyclopropanols with sulfonyl oxime ethers. Organic and Biomolecular Chemistry, 2020, 18, 3734-3739.	1.5	21
54	Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone. Psychopharmacology, 2015, 232, 3309-3318.	1.5	20

#	Article	IF	CITATIONS
55	Neuropeptide FF and Its Receptors: Therapeutic Applications and Ligand Development. Journal of Medicinal Chemistry, 2020, 63, 12387-12402.	2.9	20
56	Role of trace amineâ€ʿassociated receptor 1 in the medial prefrontal cortex in chronic social stress-induced cognitive deficits in mice. Pharmacological Research, 2021, 167, 105571.	3.1	20
57	Peripherally Selective Diphenyl Purine Antagonist of the CB1 Receptor. Journal of Medicinal Chemistry, 2013, 56, 8066-8072.	2.9	19
58	Pyrazole antagonists of the CB1 receptor with reduced brain penetration. Bioorganic and Medicinal Chemistry, 2016, 24, 1063-1070.	1.4	19
59	Chitosan and dextran stabilized GO-iron oxide nanosheets with high dispersibility for chemotherapy and photothermal ablation. Ceramics International, 2019, 45, 5996-6003.	2.3	19
60	Hypocretin receptor 1 involvement in cocaine-associated behavior: Therapeutic potential and novel mechanistic insights. Brain Research, 2020, 1731, 145894.	1.1	19
61	TA ₁ agonists attenuate extendedâ€access cocaine selfâ€administration and yohimbineâ€induced reinstatement of cocaineâ€seeking. British Journal of Pharmacology, 2020, 177, 3403-3414.	2.7	19
62	Conformationally Constrained Analogues of N-(Piperidinyl)-5-(4-Chlorophenyl)-1-(2,4-) Tj ETQq0 0 0 rgBT /Overloc Analysis, And Biological Evaluations. Journal of Medicinal Chemistry, 2008, 51, 3526-3539.	k 10 Tf 50 2.9	9 467 Td (Dic 18
63	Truncated Orexin Peptides: Structure–Activity Relationship Studies. ACS Medicinal Chemistry Letters, 2013, 4, 1224-1227.	1.3	18
64	Discriminative stimulus effects of the imidazoline I2 receptor ligands BU224 and phenyzoline in rats. European Journal of Pharmacology, 2015, 749, 133-141.	1.7	18
65	Effects of a trace amine-associated receptor 1 agonist RO 5263397 on ethanol-induced behavioral sensitization. Behavioural Brain Research, 2020, 390, 112641.	1.2	18
66	Regioselective Couplings of Dibromopyrrole Esters. Synthesis, 2006, 2006, 3883-3887.	1.2	17
67	The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 5709-5724.	1.4	17
68	Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2980-2985.	1.0	16
69	Effects of imidazoline I2 receptor agonists and morphine on schedule-controlled responding in rats. Pharmacology Biochemistry and Behavior, 2012, 101, 354-359.	1.3	16
70	Time-economical synthesis of selenofunctionalized heterocycles <i>via</i> I ₂ O ₅ -mediated selenylative heterocyclization. Organic and Biomolecular Chemistry, 2022, 20, 420-426.	1.5	16
71	Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS Journal, 2006, 8, E665-E671.	2.2	15
72	Mechanisms of imidazoline I ₂ receptor agonistâ€induced antinociception in rats: involvement of monoaminergic neurotransmission. British Journal of Pharmacology, 2018, 175, 1519-1534.	2.7	15

#	Article	IF	CITATIONS
73	Nickel(II)-Catalyzed Borylation of Alkenyl Methyl Ethers via C–O Bond Cleavage. Organic Letters, 2020, 22, 6424-6428.	2.4	15
74	ldentification of <i>N</i> -[(5-{[(4-Methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1 <i>H</i> -indol-1-yl)acetyl]- <scp>l</scp> -leuci (NTRC-824), a Neurotensin-like Nonpeptide Compound Selective for the Neurotensin Receptor Type 2. Journal of Medicinal Chemistry, 2014, 57, 7472-7477.	ne 2.9	14
75	Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor. ACS Chemical Neuroscience, 2015, 6, 599-614.	1.7	14
76	The imidazoline I2 receptor agonist 2-BFI attenuates hypersensitivity and spinal neuroinflammation in a rat model of neuropathic pain. Biochemical Pharmacology, 2018, 153, 260-268.	2.0	14
77	Activation of trace amineâ€associated receptor 1 selectively attenuates the reinforcing effects of morphine. British Journal of Pharmacology, 2021, 178, 933-945.	2.7	14
78	Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior. Drug and Alcohol Dependence, 2021, 224, 108719.	1.6	14
79	Antinociceptive effects of imidazoline I2 receptor agonists in the formalin test in rats. Behavioural Pharmacology, 2016, 27, 377-383.	0.8	13
80	Discriminative stimulus effects of the novel imidazoline I2 receptor ligand CR4056 in rats. Scientific Reports, 2014, 4, 6605.	1.6	12
81	The progresses in curcuminoids-based metal complexes: especially in cancer therapy. Future Medicinal Chemistry, 2019, 11, 1035-1056.	1.1	12
82	Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators. Journal of Medicinal Chemistry, 2019, 62, 9806-9823.	2.9	12
83	Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. Journal of Medicinal Chemistry, 2021, 64, 8806-8825.	2.9	12
84	Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice. European Journal of Pharmacology, 2012, 695, 62-70.	1.7	11
85	Identification of Neuropeptide S Antagonists: Structure–Activity Relationship Studies, X-ray Crystallography, and in Vivo Evaluation. ACS Chemical Neuroscience, 2014, 5, 731-744.	1.7	11
86	Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats. Psychopharmacology, 2017, 234, 1871-1880.	1.5	11
87	Encapsulation and pH-responsive release of bortezomib by dopamine grafted hyaluronate nanogels. International Journal of Biological Macromolecules, 2021, 183, 369-378.	3.6	11
88	Gender difference in epileptogenic effects of 2-BFI and BU224 in mice. European Journal of Pharmacology, 2013, 718, 81-86.	1.7	10
89	Effects of imidazoline I2 receptor agonists on reserpine-induced hyperalgesia and depressive-like behavior in rats. Behavioural Pharmacology, 2019, 30, 429-434.	0.8	10
90	Preparing molecularly imprinted nanoparticles of saponins via cooperative imprinting strategy. Journal of Separation Science, 2020, 43, 2162-2171.	1.3	10

Yanan Zhang

#	Article	IF	CITATIONS
91	Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists. ACS Chemical Neuroscience, 2017, 8, 2290-2308.	1.7	10
92	Interactions between imidazoline I2 receptor ligands and acetaminophen in adult male rats: antinociception and schedule-controlled responding. Psychopharmacology, 2016, 233, 873-882.	1.5	9
93	Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats. Behavioural Pharmacology, 2017, 28, 590-593.	0.8	9
94	Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chemical Neuroscience, 2018, 9, 587-602.	1.7	9
95	Diarylureas Containing 5-Membered Heterocycles as CB ₁ Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation. ACS Chemical Neuroscience, 2019, 10, 518-527.	1.7	8
96	Activation of trace amineâ€associated receptor 1 attenuates nicotine withdrawalâ€related effects. Addiction Biology, 2022, 27, e13075.	1.4	8
97	Behavioral effects of the imidazoline I2 receptor ligand BU99006 in rats. Behavioural Pharmacology, 2014, 25, 130-136.	0.8	7
98	Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorganic and Medicinal Chemistry, 2021, 41, 116215.	1.4	7
99	Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. Journal of Medicinal Chemistry, 2022, 65, 257-270.	2.9	7
100	Tumor microenvironment-activatable boolean logic supramolecular nanotheranostics based on a pillar[6]arene for tumor hypoxia imaging and multimodal synergistic therapy. Materials Chemistry Frontiers, 2021, 5, 5846-5856.	3.2	6
101	Nanonickel Oxides Prepared by Atomic Layer Deposition as Efficient Catalyst for the Dehydrogenation of Nâ€Heterocycles. ChemistrySelect, 2020, 5, 11811-11816.	0.7	5
102	Role of intracellular Ca2+ signaling in the antinociceptive and discriminative stimulus effects of the imidazoline I2 receptor agonist 2-BFI in rats. Psychopharmacology, 2017, 234, 3299-3307.	1.5	4
103	Neuroanatomical characterization of imidazoline I ₂ receptor agonistâ€induced antinociception. European Journal of Neuroscience, 2018, 47, 1087-1095.	1.2	4
104	The selective TAAR1 partial agonist RO5263397 promoted novelty recognition memory in mice. Psychopharmacology, 2021, 238, 3221-3228.	1.5	4
105	Synthesis of Enantiopure PZM21: A Biased Agonist of the Muâ€Opioid Receptor. European Journal of Organic Chemistry, 2018, 2018, 4006-4012.	1.2	3
106	TAAR1 regulates drug-induced reinstatement of cocaine-seeking via negatively modulating CaMKIIα activity in the NAc. Molecular Psychiatry, 2022, 27, 2136-2145.	4.1	3
107	Neuropeptide B/W receptor 1 peptidomimetic agonists: Structure-activity relationships and plasma stability. European Journal of Medicinal Chemistry, 2022, 231, 114149.	2.6	3
108	RTICBM-74 Is a Brain-Penetrant Cannabinoid Receptor Subtype 1 Allosteric Modulator that Reduces Alcohol Intake in Rats. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 153-161.	1.3	3

#	Article	lF	CITATIONS
109	Modified Synthesis of NOP Receptor Antagonist SB612111. Synthesis, 2017, 49, 1394-1400.	1.2	2
110	Nickel(ii)-catalyzed reductive silylation of alkenyl methyl ethers for the synthesis of alkyl silanes. RSC Advances, 2021, 11, 37083-37088.	1.7	2
111	Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core. Pharmaceuticals, 2021, 14, 1024.	1.7	1
112	Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EGâ€018. Pharmacology Research and Perspectives, 2022, 10, e00901.	1.1	1
113	Protection of Poorly Nucleophilic Pyrroles ChemInform, 2004, 35, no.	0.1	0
114	InÂvitro and in vivo evaluation of virus-induced innate immunity in mouse. STAR Protocols, 2021, 2, 100708.	0.5	0